Literature DB >> 12527303

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.

S Krapp1, Y Mimura, R Jefferis, R Huber, P Sondermann.   

Abstract

Antibodies may be viewed as adaptor molecules that provide a link between humoral and cellular defence mechanisms. Thus, when antigen-specific IgG antibodies form antigen/antibody immune complexes the effectively aggregated IgG can activate a wide range of effector systems. Multiple effector mechanisms result from cellular activation mediated through a family of IgG-Fc receptors differentially expressed on leucocytes. It is established that glycosylation of IgG-Fc is essential for recognition and activation of these ligands. IgG antibodies predominate in human serum and most therapeutic antibodies are of the IgG class. The IgG-Fc is a homodimer of N-linked glycopeptide chains comprised of two immunoglobulin domains (Cgamma2, Cgamma3) that dimerise via inter-heavy chain disulphide bridges at the N-terminal region and non-covalent interactions between the C-terminal Cgamma3 domains. The overall shape of the IgG-Fc is similar to that of a "horseshoe" with a majority of the internal space filled by the oligosaccharide chains, only attached through asparagine residues 297.To investigate the influence of individual sugar (monosaccharide) residues of the oligosaccharide on the structure and function of IgG-Fc we have compared the structure of "wild-type" glycosylated IgG1-Fc with that of four glycoforms bearing consecutively truncated oligosaccharides. Removal of terminal N-acetylglucosamine as well as mannose sugar residues resulted in the largest conformational changes in both the oligosaccharide and in the polypeptide loop containing the N-glycosylation site. The observed conformational changes in the Cgamma2 domain affect the interface between IgG-Fc fragments and FcgammaRs. Furthermore, we observed that the removal of sugar residues permits the mutual approach of Cgamma2 domains resulting in the generation of a "closed" conformation; in contrast to the "open" conformation which was observed for the fully galactosylated IgG-Fc, which may be optimal for FcgammaR binding. These data provide a structural rationale for the previously observed modulation of effector activities reported for this series of proteins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527303     DOI: 10.1016/s0022-2836(02)01250-0

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  216 in total

1.  Improving mass accuracy of high performance liquid chromatography/electrospray ionization time-of-flight mass spectrometry of intact antibodies.

Authors:  Himanshu S Gadgil; Gary D Pipes; Thomas M Dillon; Michael J Treuheit; Pavel V Bondarenko
Journal:  J Am Soc Mass Spectrom       Date:  2006-04-21       Impact factor: 3.109

2.  Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Authors:  Shan Chung; Valerie Quarmby; Xiaoying Gao; Yong Ying; Linda Lin; Chae Reed; Chris Fong; Wendy Lau; Zhihua J Qiu; Amy Shen; Martin Vanderlaan; An Song
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

3.  Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates.

Authors:  Mauro Acchione; Hyewon Kwon; Claudia M Jochheim; William M Atkins
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 4.  Lepidopteran cells, an alternative for the production of recombinant antibodies?

Authors:  Martine Cérutti; Josée Golay
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

5.  Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Hannah Joerissen; Beate Müller-Tiemann; Heiner Apeler; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-03       Impact factor: 2.695

Review 6.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

7.  Impact of Glycosylation on the Local Backbone Flexibility of Well-Defined IgG1-Fc Glycoforms Using Hydrogen Exchange-Mass Spectrometry.

Authors:  Apurva S More; Ronald T Toth; Solomon Z Okbazghi; C Russell Middaugh; Sangeeta B Joshi; Thomas J Tolbert; David B Volkin; David D Weis
Journal:  J Pharm Sci       Date:  2018-05-08       Impact factor: 3.534

8.  Immunoglobulin G1 Fc domain motions: implications for Fc engineering.

Authors:  Martin Frank; Ross C Walker; William N Lanzilotta; James H Prestegard; Adam W Barb
Journal:  J Mol Biol       Date:  2014-02-09       Impact factor: 5.469

Review 9.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

10.  IgG4 can induce an M2-like phenotype in human monocyte-derived macrophages through FcγRI.

Authors:  Jennifer F A Swisher; Devin A Haddad; Anna G McGrath; Gunther H Boekhoudt; Gerald M Feldman
Journal:  MAbs       Date:  2014       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.